INTRODUCTION
============

Diabetes mellitus (DM) is a serious and growing health problem worldwide and is associated with severe acute and chronic complications. Today, 250 million people live with diabetes globally, and this figure is expected to reach 366 million in 2030 \[[@B1]\]. Therefore, if diabetes is associated with an increase in the risk of cancer, this may have a tremendous impact on health worldwide. The industrialization and economic growth accompanied by the so-called \'westernization\' of lifestyle, characterized by a high-calorie diet, obesity, and physical inactivity may explain this diabetes epidemic. As a result of this change, the mortality of lifestyle-related diseases such as cancer, diabetes, and cardiovascular disease has increased in many countries including South Korea. Worldwide, cancer is the 2nd and diabetes is the 12th leading cause of death \[[@B2]\]. According to the recent Statistics Korea report for 2009 \[[@B3]\], cancer is the leading cause of death and DM is the 5th most common cause of death.

Epidemiologic evidence suggests that people with diabetes are at significantly higher risk for many forms of cancer \[[@B4]-[@B7]\]. Park et al. \[[@B8]\] found that death by malignancy was markedly increased (from 4.7% to 21.9%) in Korean type 2 diabetes patients during the past 10 years. Type 2 diabetes and cancer share many risk factors, but potential biologic links between the two diseases are not completely understood.

In this review, we will discuss Korean and foreign evidences of an association between diabetes and cancer, and the possible mechanisms involved. The link between diabetes treatment and cancer risk will also be reviewed.

INCREASED CANCER INCIDENCE IN DIABETIC PATIENTS
===============================================

Many longitudinal and case-control studies, often pooled in meta-analyses, have explored the association between diabetes and a large array of different neoplasms. Recently, the results of several studies have been combined for a meta-analytic study \[[@B4],[@B9]\] and the results are shown in [Table 1](#T1){ref-type="table"}. The relative risks imparted by diabetes are greatest (about twofold or higher) for cancers of the liver, pancreas, and endometrium, and lesser (about 1.2 to 1.5 fold) for cancers of the colon and rectum, breast, and bladder. Other cancers (such as lung) do not appear to be associated with diabetes, and the evidence for some (e.g., kidney, non-Hodgkin\'s lymphoma) is inconclusive. Diabetes is associated with a lower risk of prostate cancer only.

Previous meta-analyses are mainly derived from Western populations. However, a 10-year prospective cohort study of 1.3 million Koreans aged 30 to 95 years \[[@B10]\] found that cancer incidence is generally elevated for persons with diabetes or an elevated fasting serum glucose level greater than 125 mg/dL (6.9 mmol/L) compared with those without hyperglycemia. The association was strongest for pancreatic cancer, comparing the highest and lowest strata in men (hazard ratio \[HR\], 1.91; 95% confidence interval \[CI\], 1.52 to 2.41) and in women (HR, 2.05; 95% CI, 1.43 to 2.93). Significant associations were also found for cancers of the esophagus, liver, and colon/rectum in men and of the liver and cervix in women. There were also significant trends with glucose level and cancers of the esophagus, colon/rectum, liver, pancreas, and bile duct in men and of the liver and pancreas in women. We also have reported that 30% of pancreatic cancer patients have diabetes \[[@B11]\]. Findings similar to those of the Korean cohort study were seen in the Japan Pubic Health Center-based Prospective (JPHC) study of 110,000 Japanese aged 40 to 60 years \[[@B12]\].

The large majority of the epidemiologic data on cancer incidence and mortality has been obtained from type 2 diabetic patients. Because of the different physiology between the two subtypes of diabetes, these findings cannot be extended to type 1 diabetic patients. However, the risk of cancer among patients with type 1 diabetes (T1DM) has been investigated in two cohort studies. A Swedish study of over 29,000 T1DM patients revealed an overall 20% increase in the risk of cancer \[[@B13]\]. In particular, the risks of stomach, uterine cervix, and endometrium neoplasm were almost doubled. A UK study involving 28,900 individuals showed that the risk of ovarian cancer and the mortality associated with this neoplasm was more than two-fold higher in subjects with T1DM than in controls \[[@B14]\]. No other significant associations were found.

INCREASED CANCER MORTALITY IN DIABETIC PATIENTS
===============================================

Besides its role as an independent risk factor for the development of several tumors, diabetes can also have impact on cancer prognosis. Several studies have documented increased cancer mortality in subjects with diabetes. A recent meta-analysis of 23 studies comparing overall survival in cancer patients with and without preexisting diabetes showed that diabetes was associated with an increased mortality HR of 1.41 (95% CI, 1.28 to 1.55) compared with normoglycemic individuals across all cancer types \[[@B15]\]. Subgroup analyses by cancer type showed an increased risk for cancers of the endometrium (HR, 1.76; 95% CI, 1.34 to 2.31), breast (HR, 1.61; 95% CI, 1.46 to 1.78), and colorectum (HR, 1.32; 95% CI, 1.24 to 1.41). A cohort study including Korean individuals \[[@B10]\] of both genders revealed a linear trend of increasing mortality with increasing fasting serum glucose levels, even in the non-diabetic range. The linear association between fasting serum glucose levels and cancer mortality was particularly evident for malignancies of the pancreas, colon/rectum, liver, esophagus, and biliary tract among men and the pancreas, liver, and uterine cervix in women.

COMMON RISK FACTORS FOR BOTH CANCER AND DIABETES
================================================

Diabetes and cancer represent common health concerns, and they often coexist in the same individuals. Overall, 8% to 18% of individuals suffering from cancer also have diabetes, and prevalence rates vary according to tumor sites \[[@B16]\].

Age
---

Over 60% of cancer diagnoses are made in individuals aged 65 years or more \[[@B17]\]; since the prevalence of diabetes reaches 17% in this age class, the coexistence of diabetes and cancer is destined to raise as life expectancy increases.

Obesity
-------

Type 2 diabetes is strongly related to overweight and obesity, two conditions associated with an increased risk of several cancers \[[@B18]\]. Cancers most consistently associated with overweight and obesity are breast (in postmenopausal women), colon/rectum, endometrium, pancreas, adenocarcinoma of the esophagus, kidney, gallbladder, and liver. Moreover, obesity is associated with higher cancer incidence and mortality \[[@B19],[@B20]\].

Physical inactivity
-------------------

Evidence from observational epidemiologic studies consistently shows that higher levels of physical activity are associated with a lower risk of the colon, postmenopausal breast, and endometrial cancer \[[@B21],[@B22]\]. Prevention of diabetes with increased physical activity has been proven by numerous trials \[[@B23]-[@B26]\].

Smoking
-------

It is estimated that worldwide, cigarette smoking accounts for 71% of all trachea, bronchus, and lung cancer deaths \[[@B27]\]. Other cancers strongly associated with smoking are cancers of the larynx, upper digestive tract, bladder, kidney, pancreas, liver, stomach, uterine cervix, and leukemia. Studies suggest that smoking is also an independent risk factor for the development of diabetes \[[@B28],[@B29]\].

POSSIBLE MECHANISMS UNDERLYING DIABETES AND CANCER
==================================================

The role of insulin in promoting cancer growth was first recognized by studies in experimental animals as early as 1972 \[[@B30],[@B31]\]. Diabetes is generally characterized by hyperglycemia and hyperinsulinemia, which are often coupled with a reduced metabolic effect of insulin (insulin resistance) in peripheral tissues. Chronic hyperinsulinemia, however, is a possible factor favoring cancer initiation and progression in diabetic patients due to the mitogenic effect of insulin, which has been reviewed in detail \[[@B32]\]. In brief, an increase in insulin levels leads to a decrease in the liver synthesis and blood levels of insulin-like growth factor binding protein 1 (IGFBP1), and is associated with a decrease in IGFBP2 in the blood. These effects in turn result in an increase in bioavailable IGF1. Insulin and IGF1 signal through insulin receptors and IGF1 receptors, respectively, to promote cellular proliferation and inhibit apoptosis in many tissue types. These effects might contribute to cancerogenesis.

Many cancer cells have increased insulin receptor (IR) content \[[@B33]\]. In malignant cells, the expression of the isoform (IR-A) is predominant, and its activation elicits more mitogenetic than metabolic effects \[[@B34]\]. By binding to the overexpressed IR-A, insulin may favor cancer progression and facilitate the growth of tumors that would otherwise have likely remained clinically irrelevant.

Insulin mitogenic activity might be enhanced at the cellular level by post-receptor molecular mechanisms, including insulin (or its synthetic analogs) residence time on the receptor \[[@B35]\] and the intracellular up-regulation of the insulin mitogenic pathway.

DIABETES TREATMENT AND CANCER
=============================

Most diabetic patients are treated for years or decades with a variety of drugs. The potential role of these drugs in favoring cancer is unclear, but is most likely minor, if any. The data are not conclusive because the large majority of diabetic patients change the drug dosage and/or type many times during the course of the disease. Moreover, many are treated with more than one drug simultaneously. As a result, this issue is not well-studied epidemiologically, and evidence is weak, inconclusive and controversial. The debate about the potential risk of developing cancer associated with insulin use has been ignited by the publication of four observational studies \[[@B36]-[@B39]\] in 2009. However, randomized clinical trial data from an open-label 5-year trial of insulin glargine versus NPH insulin did not find any evidence of excess cancer risk with insulin glargine \[[@B40]\]. Due to the methodological limitations of previous studies, which have been broadly debated \[[@B41]-[@B43]\], a clear relationship between use of insulin glargine and increased risk of cancer cannot be established.

On the contrary, a mounting body of evidence suggests that metformin may reduce cancer risk \[[@B36],[@B44]-[@B47]\] or mortality \[[@B48]\] in diabetic patients. There is probably a dual mechanism for the anticancer effect of metformin. In addition to the lowering of circulating levels of insulin, metformin stimulates expression of AMPK, leading to the rapid inhibition of cellular protein synthesis and growth \[[@B49],[@B50]\].

CONCLUSION
==========

Descriptive and analytical evidence obtained to date suggest that cancer risk and cancer mortality are increased in diabetic patients, providing more evidence for some site-specific cancers. The increase in the risk of cancer is likely related to the interplay between obesity, hyperinsulinemia and hyperglycemia. Improved glycemic control guidelines with a wide prescription of statin and aspirin have reduced death from vascular complications and diabetes itself. As a result, death by cancer is rising steeply although cardiovascular disease and infection are still the leading cause of the death. The impressive rate of increase in the incidence of both diabetes and obesity will pose serious problems to many countries including South Korea. In order to fight the perfect storm of diabetes and cancer, preventive strategies to promote primary prevention and early detection of these conditions are urgently needed.
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CI, confidence interval.

^a^Kidney cancer data was not obtained from meta-analysis.
